Results 121 to 130 of about 8,073 (181)

Patient rights in precision oncology: right treatment, right time, right dose, right order, right place. [PDF]

Genome Med
Fountzilas E, Tsimberidou AM, Kurzrock R.   +2 more
europepmc   +1 more source

The Coiled Coil and C2 Domains Modulate BCR Localization and BCR-ABL1 Compartmentalization, Transforming Activity and TKI Responsiveness. [PDF]

Int J Mol Sci
Massimino M, Stella S, Romano C, Buffa P, Tirrò E, Drago M, Manzella L, Tomarchio C, Vitale SR, Di Raimondo F, Vigneri P.   +10 more
europepmc   +1 more source

Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia. [PDF]

Clin Epigenetics
Yang H, Li V, Park SJ, Cheon SW, Lorant A, Mazumder A, Lee JY, Orlikova-Boyer B, Cerella C, Christov C, Kirsch G, Olberg DE, Bormans G, Kang HJ, Han BW, Schnekenburger M, Diederich M.   +16 more
europepmc   +1 more source

Bosutinib-Induced Pleural Effusion-Class Effect and Cross-Intolerance to All Tyrosine Kinase Inhibitors. [PDF]

Hematol Rep
Vojjala N, Sami HA, Kotla NK, Peshin S, Goyal K, Kondaveety S, Prabhu RR, Krishnamoorthy G.   +7 more
europepmc   +1 more source

Allele-Specific PCR for Detection of Missense Mutations in the Chimeric <i>BCR::ABL1</i> Gene Causing Failure of Tyrosine Kinase Inhibitor Therapy in CML Patients. [PDF]

Int J Mol Sci
Skripkina A, Fevraleva I, Kuzmina E, Biderman B, Stepanova E, Chelysheva E, Turkina A, Sudarikov A.   +7 more
europepmc   +1 more source

Real-world comparison of flumatinib and nilotinib as first-line therapy for patients with chronic phase chronic myeloid leukemia: a multicenter retrospective study. [PDF]

Ther Adv Med Oncol
Lei Y, Zhao X, Qiao C, Hong M, Qian S, Li J, Li W, Zhu Y.   +7 more
europepmc   +1 more source

The efficacy and safety of asciminib treatment in patients with chronic myeloid leukemia as a second-line or beyond second-line treatment: a systematic review and meta-analysis. [PDF]

Ther Adv Hematol
Fan Z, Xie J, Su P, Tai J, Feng W, Xu R, Ouyang Y.   +6 more
europepmc   +1 more source

No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the <i>BCR::ABL1</i> Transcript Level. [PDF]

Int J Mol Sci
Stagno F, Stella S, Leotta S, Caserta S, Vitale SR, Markovic U, Tomarchio C, Mirabile G, Russo S, Massimino M, Vigneri P, Manzella L, Di Raimondo F, Allegra A.   +13 more
europepmc   +1 more source

Treatment-Emergent Resistance to Asciminib in Chronic Myeloid Leukemia Patients Due to Myristoyl-Binding Pocket-Mutant of <i>BCR::ABL1/A337V</i> Can Be Effectively Overcome with Dasatinib Treatment. [PDF]

Curr Oncol
Batar P, Mezei G, Illes A.
europepmc   +1 more source